Delivery Order SPE2DB24D1201-SPE2DB25FJDZU
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $37,531.67 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price, competitively awarded contract (no set-aside used) is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat atopic dermatitis, eosinophilic esophagitis, and asthma,...
- The Defense Logistics Agency awarded a delivery order valued at $103,490.97 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 29, 2025, with an ultimate completion date of July 30, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The pharmaceutical product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. Dupixent is a biologic...
- The Defense Logistics Agency awarded a $68,986.58 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-competitive delivery order represents a firm fixed price transaction under an existing Indefinite Delivery Contract vehicle. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $50,616.79 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 20, 2025, with completion expected by August 21, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and other...
- The Defense Logistics Agency awarded a delivery order valued at $23,046.15 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injections on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement of pharmaceutical supplies performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions...
- The Defense Logistics Agency awarded a delivery order valued at $10,813.19 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 13, 2025, with an ultimate completion date of August 14, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat moderate-to-severe eczema, asthma, and...
- The Defense Logistics Agency awarded a delivery order valued at $3,418.92 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectables on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and is being fulfilled from AmerisourceBergen's place of business in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded a $26,328.21 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml units). This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a delivery order valued at $42,788.32 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on July 21, 2025, with completion expected by July 22, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic...
- The Defense Logistics Agency awarded a $11,417.33 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on August 19, 2025, with completion targeted for August 20, 2025. This firm fixed-price, competitively awarded delivery order was issued without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a prescription biologic medication primarily used to treat...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJDZUDelivery Order
The Defense Logistics Agency awarded a $54,501.62 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 27, 2025, with ultimate completion by August 28, 2025. This firm fixed-price, competitively awarded contract—without set-aside designation—will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, representing part of DLA's critical pharmaceutical supply chain for military and federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, has demonstrated extensive capability fulfilling federal medical procurement requirements through open competition, supplying a diverse portfolio of specialty medications, vaccines, and medical supplies to support Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $54.5k | 8/27/25 |